Ascendis Pharma reports Q4 EPS (EUR 0.55) vs. (EUR 0.64) last year

Reports Q4 revenue EUR 247.5M vs. EUR 173.92M last year. “With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,” said Jan Mikkelsen, president and CEO of Ascendis Pharma (ASND). “With strong execution and the power of our TransCon platform, we are positioned to generate approximately EUR 500 million in operating cash flow in 2026 while aspiring to deliver at least EUR 5 billion in global annual product revenue by 2030. At the same time, we are advancing a growing pipeline of highly differentiated programs to deliver durable, long-term growth.”